FindTrial
Sign In

The role of peripheral blood plasma blastocyte level in monitoring the activity of targeted B cell therapy in SLE

The role of peripheral blood plasma blastocyte level in monitoring the activity of targeted B cell therapy in SLE

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500096214
Enrollment
Unknown
Registered
2025-01-20
Start date
2025-01-20
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

The Beliumab group:None
The Taitasep group:None

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with systemic lupus erythematosus: Patients with SLE who met the 1997 ACRSLE diagnostic criteria or the 2019 EULAR/ACR classification diagnostic criteria for systemic lupus erythematosus and still had high disease activity (positive anti-DSDNA antibodies and low complement or SELENA-SLEDAI score =8) on the basis of conventional treatment, and did not have other connective tissue diseases.

Exclusion criteria

Exclusion criteria: Patients with other autoimmune diseases, severe infections, heart, liver, brain diseases, and malignant tumors

Design outcomes

Primary

MeasureTime frame
anti-dsDNA antibody;complement 3;complement 4;plasmoblast cell;—

Countries

China

Contacts

Public ContactHua Wei

Northern Jiangsu People's Hospital

yzweihua2018@163.com+86 180 5106 1177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026